172 related articles for article (PubMed ID: 14988528)
1. SARS treatment. Interferon shows promise in monkeys.
Enserink M
Science; 2004 Feb; 303(5662):1273-5. PubMed ID: 14988528
[No Abstract] [Full Text] [Related]
2. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques.
Haagmans BL; Kuiken T; Martina BE; Fouchier RA; Rimmelzwaan GF; van Amerongen G; van Riel D; de Jong T; Itamura S; Chan KH; Tashiro M; Osterhaus AD
Nat Med; 2004 Mar; 10(3):290-3. PubMed ID: 14981511
[TBL] [Abstract][Full Text] [Related]
3. [Preventive and therapeutic effects of recombinant IFN-alpha2b nasal spray on SARS-CoV infection in Macaca mulata].
Gao H; Zhang LL; Wei Q; Duan ZJ; Tu XM; Yu ZA; Deng W; Zhang LP; Bao LL; Zhang B; Tong W; Hou YD; Zhang BL; Huang L; Qin C
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):207-10. PubMed ID: 16261198
[TBL] [Abstract][Full Text] [Related]
4. [A field trial of recombinant human interferon alpha-2b for nasal spray to prevent SARS and other respiratory viral infections].
Yu DX; Chen Q; Zhang LL; Liu Y; Yu ZA; Li ZF; Zhang LP; Hu GF; Duan ZJ; Chu XW; Zhang B; Yu SY; Hou YD
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):216-9. PubMed ID: 16261200
[TBL] [Abstract][Full Text] [Related]
5. [A field trial for evaluating the safety of recombinant human interferon alpha-2b for nasal spray].
Chen Q; Zhang LL; Yu DX; Yu ZA; Liu Y; Zhang LP; Li ZF; Duan ZJ; Wang BH; Wei XJ; Hu GF; Liu YQ; Chu XW; Han YH; Wu M; Jiang XL; Li JD; Dai YC; Nie J; Long J; Zhu L; Sun SX; Rui YY; Zhang DK; Yu SY; Hou YD
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):211-5. PubMed ID: 16261199
[TBL] [Abstract][Full Text] [Related]
6. Infectious diseases. One year after outbreak, SARS virus yields some secrets.
Enserink M
Science; 2004 May; 304(5674):1097. PubMed ID: 15155925
[No Abstract] [Full Text] [Related]
7. [Anti-SARS virus activities of different recombinant human interferons in cell culture system].
Duan ZJ; Zhang LL; Xie ZP; Yu ZA; Zhang LP; Zhang B; Liu YQ; Wang JW; Li WP; Zhang CH; Ma XJ; Shu YL; Duan SM; Li DX; Hou YD
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Sep; 17(3):205-8. PubMed ID: 15340558
[TBL] [Abstract][Full Text] [Related]
8. [Emergency treatment for Middle Eastern coronaviruses (MERS-CoV].
Nau JY
Rev Med Suisse; 2013 Jun; 9(392):1394-5. PubMed ID: 23882919
[No Abstract] [Full Text] [Related]
9. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha.
Ströher U; DiCaro A; Li Y; Strong JE; Aoki F; Plummer F; Jones SM; Feldmann H
J Infect Dis; 2004 Apr; 189(7):1164-7. PubMed ID: 15031783
[TBL] [Abstract][Full Text] [Related]
10. Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.
Kumaki Y; Day CW; Wandersee MK; Schow BP; Madsen JS; Grant D; Roth JP; Smee DF; Blatt LM; Barnard DL
Biochem Biophys Res Commun; 2008 Jun; 371(1):110-3. PubMed ID: 18406349
[TBL] [Abstract][Full Text] [Related]
11. Severe acute respiratory syndrome treatment: present status and future strategy.
Lau AC; So LK
Curr Opin Investig Drugs; 2003 Aug; 4(8):918-20. PubMed ID: 14508874
[No Abstract] [Full Text] [Related]
12. Development of antiviral therapy for severe acute respiratory syndrome.
Cinatl J; Michaelis M; Hoever G; Preiser W; Doerr HW
Antiviral Res; 2005 Jun; 66(2-3):81-97. PubMed ID: 15878786
[TBL] [Abstract][Full Text] [Related]
13. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets.
ter Meulen J; Bakker AB; van den Brink EN; Weverling GJ; Martina BE; Haagmans BL; Kuiken T; de Kruif J; Preiser W; Spaan W; Gelderblom HR; Goudsmit J; Osterhaus AD
Lancet; 2004 Jun; 363(9427):2139-41. PubMed ID: 15220038
[TBL] [Abstract][Full Text] [Related]
14. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque.
Li BJ; Tang Q; Cheng D; Qin C; Xie FY; Wei Q; Xu J; Liu Y; Zheng BJ; Woodle MC; Zhong N; Lu PY
Nat Med; 2005 Sep; 11(9):944-51. PubMed ID: 16116432
[TBL] [Abstract][Full Text] [Related]
15. Treatment and vaccines for severe acute respiratory syndrome.
Groneberg DA; Poutanen SM; Low DE; Lode H; Welte T; Zabel P
Lancet Infect Dis; 2005 Mar; 5(3):147-55. PubMed ID: 15766649
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.
Momattin H; Mohammed K; Zumla A; Memish ZA; Al-Tawfiq JA
Int J Infect Dis; 2013 Oct; 17(10):e792-8. PubMed ID: 23993766
[TBL] [Abstract][Full Text] [Related]
17. Recent patents on treatment of severe acute respiratory syndrome (SARS).
Zhai S; Liu W; Yan B
Recent Pat Antiinfect Drug Discov; 2007 Jan; 2(1):1-10. PubMed ID: 18221160
[TBL] [Abstract][Full Text] [Related]
18. Treatment of SARS with human interferons.
Cinatl J; Morgenstern B; Bauer G; Chandra P; Rabenau H; Doerr HW
Lancet; 2003 Jul; 362(9380):293-4. PubMed ID: 12892961
[TBL] [Abstract][Full Text] [Related]
19. [Present state of in vitro and in vivo studies on efficacy of medical nonspecific protective agents with respect to genotype IV coronavirus causing severe acute respiratory syndrome].
Shchukina VN; Loginova SIa; Borisevich SV; Bondarev VP
Antibiot Khimioter; 2011; 56(9-10):41-6. PubMed ID: 22586904
[TBL] [Abstract][Full Text] [Related]
20. Interferon-beta 1a and SARS coronavirus replication.
Hensley LE; Fritz LE; Jahrling PB; Karp CL; Huggins JW; Geisbert TW
Emerg Infect Dis; 2004 Feb; 10(2):317-9. PubMed ID: 15030704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
